乳腺肿瘤组织生长抑素受体检测及其临床意义  

Detecting Somatostatin Receptor in Breast Tumor Tissue and Its Clinical Significance

作　　者：张永健[1] 于宪[1] 林伟[1] 丁绚[1] 黄世章[2] 陆光明[2] 

机构地区：[1]广州医学院第二附属医院核医学科,广东广州510260 [2]广州医学院第二附属医院病理科,广东广州510260

出　　处：《标记免疫分析与临床》2002年第1期33-34,共2页Labeled Immunoassays and Clinical Medicine

摘　　要：探讨乳腺良、恶性肿瘤SSR表达的差异对乳腺肿瘤良、恶性的鉴别诊断的价值 ,观察SSR表达与ER、PR表达的相关性 ,预测乳腺肿瘤生长抑素受体显像的临床价值。将手术切下的标本分成 4组 :乳腺肿瘤恶性组(恶性组 )及其对照组 (癌旁组 ) ,乳腺肿瘤良性组 (良性组 )及其对照组 (瘤旁组 )。采用RBA法测定各组织的SSR表达 ,采用免疫LsAB法测定ER、PR表达。结果 :(1)恶性组、癌旁组、良性组、瘤旁组SSR表达分别为10 8.6± 67.3fmol/mgpr、3 7.2± 9.6fmol/mgpr、43 .4± 12 .6fmol/mgpr、3 3 .9± 10 .2fmol/mgpr,恶性组比其对照组及良性组都高 ,差异有显著性 (P值分别为 <0 .0 0 1、<0 .0 1) ,而良性组与其对照组则无显著性差异 (P >0 .0 5 ) ;(2 )SSR与ER、PR表达的相关系数分别为 0 .85 9、0 .75 0。因此 ,大多数乳腺癌组织表达高密度的SSR ,可用SSR显像来做良、恶性肿瘤的初步鉴别 ,SSR表达与ER、PR表达有良好的相关性 。The article is to observe the difference of somatostatin receptor(SSR) between benign and malignant breast tumor and the relation between SSR and estrogen receptor(ER) or progesterone receptor(PR)in breast tumor tissue, and to predict the clinical value of detecting breast tumor by SSR receptor imaging. These tissues excised from operation in breast tumor were divided into 4 groups: breast malignant tumor group(BMTG) and its control group(C1G), breast benign tumor group (BBTG) and its control group(C2G). SSR was detected by radioligand binding assay(RBA) and ER, PR by LsAB method in these groups. Results is: (1)The SSR express quantity is 108.6±67.3fmol/mg pr, 37.2±9.6fmol/mg pr, 43.4± 12.6 fmol/mg pr 33.9±10.2fmol/mg pr respectively in BMTG, C1G, BBTG, C2G. The SSR of BMTG is the most among these groups, the difference is obvious, P <0.001 and P <0.01 respectively compared with C1G and BBTG, no notable difference is found between BBTG and C2G ( P >0.05);(2)The correlation coefficient of SSR and ER is 0.859, SSR and PR is 0.750. Most breast tumor tissues express high density SSR, we suppose that malignant tumor can been distinguished from benign tumor preliminarily by SSR receptor imaging. There is a good correlation between SSR and ER, PR, detecting SSR may predict the quality of tumor and the prognosis of the patient.

关 键 词：乳腺肿瘤 生长抑素受体 放射配基结合分析 

分 类 号：R737.9[医药卫生—肿瘤]